Sensei Biotherapeutics to Participate in Citi’s 2023 Virtual Oncology Leadership Summit

Rhea-AI Summary

Sensei Biotherapeutics, a leader in immuno-oncology, announced the participation of its management team in a fireside chat at the Citi 2023 Virtual Oncology Leadership Summit on February 23, 2023, at 11:00 a.m. ET. The event highlights Sensei's innovative approaches in developing next-generation therapeutics for cancer, notably through its TMAb™ platform that aims to enhance T cell activity against tumors. Interested parties can access a live webcast of the presentation, which will also be available for replay on the company’s website for 90 days post-event. Sensei’s lead candidate is SNS-101, targeting the VISTA checkpoint.

BOSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that Company management will participate in a fireside chat at Citi’s 2023 Virtual Oncology Leadership Summit, on Thursday, February 23^rd at 11:00 a.m. ET.

A webcast of Sensei’s presentation will be available in the Investors section of the Sensei website. A replay of the webcast will be on the website for approximately 90 days following the event. Registration for the live webcast is available here.

About Sensei Biotherapeutics
Sensei Biotherapeutics (NASDAQ: SNSE) is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable checkpoints and other immunosuppressive signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditional binding monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4), as well as SNS-103, also a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39. For more information, please visit www.senseibio.com, and follow the company on Twitter @SenseiBio and LinkedIn.

Investor Contact:
Michael Biega
Senior Director, Investor Relations
Sensei Biotherapeutics
mbiega@senseibio.com

Media Contact:
Chris Railey
Ten Bridge Communications
chris@tenbridgecommunications.com

FAQ

What is the date and time of Sensei Biotherapeutics' presentation at the Citi 2023 Virtual Oncology Leadership Summit?

Sensei Biotherapeutics will present at the Citi 2023 Virtual Oncology Leadership Summit on February 23, 2023, at 11:00 a.m. ET.

Where can I watch the webcast of Sensei Biotherapeutics' fireside chat?

The webcast of Sensei Biotherapeutics' fireside chat will be available in the Investors section of their website.

How long will the replay of Sensei Biotherapeutics' presentation be available?

The replay of Sensei Biotherapeutics' presentation will be available for approximately 90 days following the event.

What are the main products being developed by Sensei Biotherapeutics?

Sensei Biotherapeutics is developing several therapeutics, including SNS-101, which targets the VISTA checkpoint, as well as SNS-102 and SNS-103.

What is the stock symbol for Sensei Biotherapeutics?

The stock symbol for Sensei Biotherapeutics is SNSE.